Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesper B Andersen

Showing results (1-10 of 149) with videos related to

Pageof 15
Sort By:
Journal of Hepato-Biliary-Pancreatic Sciences|September 2, 2014
Molecular pathogenesis of intrahepatic cholangiocarcinomaJesper B Andersen
Hepatology (Baltimore, Md.)|May 4, 2022
Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinomaJesper B Andersen
Gastroenterology|March 1, 2015
Fibrolamellar hepatocellular carcinoma: a rare but distinct type of liver cancerJesper B Andersen
Hepatobiliary Surgery and Nutrition|March 14, 2018
Single cell profiling reveals window for immunotherapy in liver cancersJesper B Andersen
Nature Communications|May 11, 2023
Alternative promoters in CpG depleted regions are prevalently associated with epigenetic misregulation of liver cancer transcriptomesChirag Nepal, Jesper B Andersen
Hepatology (Baltimore, Md.)|May 8, 2025
Intrahepatic cholangiocarcinoma PANoptosidyColm J O'Rourke, Jesper B Andersen
Clinical and Molecular Hepatology|January 27, 2026
FOXM1 influences DNA methylation to augment TACC3 alternative splicing directed by KAT2A in hepatocellular carcinomaLi Na Zhao, Jesper B Andersen
Iscience|June 15, 2026
Alternative splicing regulates <i>FGGY-</i>derived neoantigen presentation and promotes immune evasion in metabolic-associated hepatocellular carcinomaLi Na Zhao, Jesper B Andersen
Gastroenterology|March 1, 2016
Heterogeneity Among Liver Cancer--A Hurdle to Optimizing TherapyNicolai Juul Birkbak, Jesper B Andersen
Hepatic Oncology|August 11, 2015
Liver cancer oncogenomics: opportunities and dilemmas for clinical applicationsJens U Marquardt, Jesper B Andersen
Pageof 15

Showing results (1-10 of 149) with videos related to

Sort By:
Pageof 15
Journal of Hepato-Biliary-Pancreatic Sciences|September 2, 2014
Molecular pathogenesis of intrahepatic cholangiocarcinomaJesper B Andersen
Hepatology (Baltimore, Md.)|May 4, 2022
Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinomaJesper B Andersen
Gastroenterology|March 1, 2015
Fibrolamellar hepatocellular carcinoma: a rare but distinct type of liver cancerJesper B Andersen
Hepatobiliary Surgery and Nutrition|March 14, 2018
Single cell profiling reveals window for immunotherapy in liver cancersJesper B Andersen
Nature Communications|May 11, 2023
Alternative promoters in CpG depleted regions are prevalently associated with epigenetic misregulation of liver cancer transcriptomesChirag Nepal, Jesper B Andersen
Hepatology (Baltimore, Md.)|May 8, 2025
Intrahepatic cholangiocarcinoma PANoptosidyColm J O'Rourke, Jesper B Andersen
Clinical and Molecular Hepatology|January 27, 2026
FOXM1 influences DNA methylation to augment TACC3 alternative splicing directed by KAT2A in hepatocellular carcinomaLi Na Zhao, Jesper B Andersen
Iscience|June 15, 2026
Alternative splicing regulates <i>FGGY-</i>derived neoantigen presentation and promotes immune evasion in metabolic-associated hepatocellular carcinomaLi Na Zhao, Jesper B Andersen
Gastroenterology|March 1, 2016
Heterogeneity Among Liver Cancer--A Hurdle to Optimizing TherapyNicolai Juul Birkbak, Jesper B Andersen
Hepatic Oncology|August 11, 2015
Liver cancer oncogenomics: opportunities and dilemmas for clinical applicationsJens U Marquardt, Jesper B Andersen
Pageof 15